Key Takeaways
- • The Delaware Supreme Court on Thursday, November 19, 2026, upheld the dismissal of a biotech investor's lawsuit seeking roughly $2 billion in damages tied to the sale of Vividion Therapeutics Inc. to Bayer Corp.
- • The court found the plaintiff investor failed to demonstrate that the alleged diversion of intellectual property reduced the merger price paid in the $2 billion transaction.
- • The ruling leaves in place the lower court's dismissal, ending the challenge to the Vividion deal's pricing on the grounds presented.
Summary
The court concluded that the investor did not show the alleged misconduct reduced the merger price. That finding was the basis for affirming the dismissal, and it addresses the central damages theory in the suit, which sought approximately $2 billion.
The primary source reporting available for this story is limited to the opening paragraphs of the Law360 article, and the remainder is behind a subscription paywall. Accordingly, details about the plaintiff's specific claims, the lower court's reasoning, and any statements from the parties are not available in this summary.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.